Arrêt de service programmé du vendredi 10 juin 16h jusqu’au lundi 13 juin 9h. Pour en savoir plus
Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests

Abstract : BACKGROUND AND AIM: There is currently no recommended time interval between noninvasive fibrosis measurements for monitoring chronic liver diseases. We determined how long a single liver fibrosis evaluation may accurately predict mortality, and assessed whether combining tests improves prognostic performance. METHODS: We included 1559 patients with chronic liver disease and available baseline liver stiffness measurement (LSM) by Fibroscan, aspartate aminotransferase to platelet ratio index (APRI), FIB-4, Hepascore, and FibroMeterV2G . RESULTS: Median follow-up was 2.8 years during which 262 (16.8%) patients died, with 115 liver-related deaths. All fibrosis tests were able to predict mortality, although APRI (and FIB-4 for liver-related mortality) showed lower overall discriminative ability than the other tests (differences in Harrell's C-index: P < 0.050). According to time-dependent AUROCs, the time period with optimal predictive performance was 2-3 years in patients with no/mild fibrosis, 1 year in patients with significant fibrosis, and <6 months in cirrhotic patients even in those with a model of end-stage liver disease (MELD) score <15. Patients were then randomly split in training/testing sets. In the training set, blood tests and LSM were independent predictors of all-cause mortality. The best-fit multivariate model included age, sex, LSM, and FibroMeterV2G with C-index = 0.834 (95% confidence interval, 0.803-0.862). The prognostic model for liver-related mortality included the same covariates with C-index = 0.868 (0.831-0.902). In the testing set, the multivariate models had higher prognostic accuracy than FibroMeterV2G or LSM alone for all-cause mortality and FibroMeterV2G alone for liver-related mortality. CONCLUSIONS: The prognostic durability of a single baseline fibrosis evaluation depends on the liver fibrosis level. Combining LSM with a blood fibrosis test improves mortality risk assessment.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Sandrine Bertrais Connectez-vous pour contacter le contributeur
Soumis le : mercredi 22 janvier 2020 - 15:36:32
Dernière modification le : jeudi 20 janvier 2022 - 12:18:02




Sandrine Bertrais, Jérôme Boursier, Alexandra Ducancelle, Frédéric Oberti, Isabelle Fouchard‐hubert, et al.. Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests. Journal of Gastroenterology and Hepatology, Wiley, 2017, 32 (6), pp.1240-1249. ⟨10.1111/jgh.13668⟩. ⟨hal-02448920⟩



Consultations de la notice